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Abstract
Estimates of preference-weighted health outcomes or health state utilities are needed to assess 
improvements in health in terms of quality-adjusted life-years. Gains in quality-adjusted life-years 
are used to assess the cost–effectiveness of prophylactic use of clotting factor compared with on-
demand treatment among people with hemophilia, a congenital bleeding disorder. Published 
estimates of health utilities for people with hemophilia vary, contributing to uncertainty in the 
estimates of cost–effectiveness of prophylaxis. Challenges in estimating utility weights for the 
purpose of evaluating hemophilia treatment include selection bias in observational data, difficulty 
in adjusting for predictors of health-related quality of life and lack of preference-based data 
comparing adults with lifetime or primary prophylaxis versus no prophylaxis living within the 
same country and healthcare system.
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Cost–effectiveness analyses assess the value of interventions, whether preventive or 
curative, in terms of expected changes in health and costs. If an intervention improves health 
outcomes and lowers total costs relative to its comparator (status quo or an alternative 
intervention), it is said to be dominant; otherwise the incremental cost–effectiveness ratio 
(ICER) is calculated as the ratio of the incremental direct cost to the incremental 
improvement in health [1,2]. A cost-utility analysis (CUA) assesses health gains using a 
quality-adjusted life-year (QALY), a preference-based summary measure that combines 
*Author for correspondence: Tel.: +1 404 498 3074 Fax: +1 404 498 6799 sgrosse@cdc.gov. 
Disclaimer
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers 
for Disease Control and Prevention.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or 
financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, 
honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.
No writing assistance was utilized in the production of this manuscript.
HHS Public Access
Author manuscript
Expert Rev Pharmacoecon Outcomes Res. Author manuscript; available in PMC 2016 April 
01.
Published in final edited form as:














information on morbidity, including quality of life and functional limitations, with 
information on premature mortality. To calculate QALYs, states of health are valued using 
QALY or ‘utility’ weights on a scale equal to 1 for perfect health and 0 for being dead.
Hemophilia A and B are hereditary bleeding disorders caused by deficiencies in clotting 
factors VIII and IX, respectively, and because they are inherited in an X-linked recessive 
pattern they mostly occur in males. Other, less common forms of hemophilia also occur. 
People with hemophilia can be categorized as having mild, moderate or severe disease based 
on the level of endogenous clotting factor activity; severe hemophilia is categorized as 
people with <1% clotting factor activity. People with severe hemophilia bleed longer than 
others after an injury and often experience internal bleeding, particularly in joints (knees, 
ankles and elbows). Conventional episodic or on-demand management of hemophilia 
involves the administration of factor concentrate to treat bleeding episodes. Routine 
prophylactic administration of factor concentrate can reduce the frequency of bleeds. 
Prophylaxis that is administered after someone with hemophilia has had associated bleeds is 
called secondary prophylaxis, whereas prophylaxis that is begun asymptomatically upon 
diagnosis in an infant or young child is called primary prophylaxis. A side effect of 
treatment with clotting factor is the development of an antibody inhibitor that can neutralize 
factor activity and make treatment ineffective. Treatments for inhibitors include immune 
tolerance therapy to eradicate the inhibitor and, if that is not successful, the use of bypassing 
agents to control bleeding.
In hemophilia management, one question has dominated the cost–effectiveness literature in 
recent years: is continuous prophylaxis cost-effective in comparison with episodic or on-
demand treatment [3]? Six CUAs of clotting factor prophylaxis in males with hemophilia 
have been published. Four reported ICERs <$75,000 US dollars or <50,000 GB pounds or 
euros [4–7]. Two other CUAs concluded that prophylaxis is very unlikely to be cost-
effective by conventional criteria, with ICERs in excess of 1 million dollars or euros [8,9]. A 
recent review by Miners of economic evaluations of hemophilia prophylaxis, consisting of 
five CEAs, five CUAs and one CBA, concluded that the diversity in estimates and 
conclusions reflected differences in local conditions and design features such as time 
horizons [3]. In addition, Miners noted that the two CUAs with the least favorable ICERs 
also assumed lower utility differences between prophylaxis and treatment on-demand than in 
three CUAs with favorable ICERs [3].
The purpose of this review is to shed light on these differences in utility estimates through a 
systematic review of the relevant literature on utility weights in patients with hemophilia. 
How sensitive are the results of CUAs of prophylaxis with clotting factor to assumptions 
about the incremental utility of prophylaxis relative to on-demand treatment? What are the 
potential biases in utility estimates that have been incorporated in CUAs of hemophilia? 
This paper does not ask whether prophylaxis is cost-effective, in part because the criteria for 
cost– effectiveness are variable and often arbitrary [10]. Some have suggested that different 
economic criteria be used, such as cost per bleed prevented or monetary benefit based on 
willingness to pay [11]. Instead, the focus of this paper is on the sources and implications of 
uncertainty in the utility scores used to assess cost–effectiveness in CUAs.
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Overview of health utility scores
Health state utilities are preference-weighted health-related quality of life (HRQL) 
measures, which use assessments of the utility or value of hypothetical health states. The US 
expert guidance recommends using utility weights based on the preferences of the general 
population or decision-makers rather than the preferences of individuals affected by a 
condition [1]. Likewise, NICE in the UK specifies the use of population-based utility scores 
in estimating QALYs for the purpose of assessing the cost–effectiveness of new drugs and 
treatments and to inform policy decisions on coverage [12]. The argument for using 
community preferences is that societal resource allocations should reflect broad community 
values [1,13,14]. Some experts argue that patient preferences, or ‘experienced utility’ as 
opposed to ex ante ‘decision utility’, should inform economic evaluations of health 
interventions [14]. It is argued that members of the general public frequently overstate the 
negative attributes of living with a condition [15]. On the other hand, patient preferences 
often do not yield higher utility weights [13]. Further, if utility weights for a condition based 
on patient preferences are very high, using them will undervalue prevention or treatments 
[14].
The foundation of the QALY measure is expected utility theory. Expected utility is the sum 
of the product of expected number of life-years and the utility of time spent in each of those 
life-years. In theory, after adjusting for time preferences via discounting, decision-makers 
should be indifferent between equivalent expected utilities, for example, 10 discounted years 
lived in perfect health followed by death versus 20 discounted years lived in a health state 
with a utility weight of 0.5. Utility weights for health states can be either directly or 
indirectly assessed. Direct utility assessment is accomplished by asking people to rate health 
states relative to death using a variety of elicitation methods. Indirect utility elicitation 
entails asking people to assess their own health according to a questionnaire with specified 
domains of health and then valuing those health states through a separate mechanism in 
which a general population sample is asked to value hypothetical combinations of health 
domains (see below for details).
As seen in Table 1, three commonly used direct elicitation methods are the standard gamble 
(SG), time trade off (TTO) and visual analogue scale (VAS) [16,17]. The SG and TTO 
methods require respondents to explicitly trade off between health states and risk of death or 
life expectancy. SG requires respondents to choose between two profiles, one of which 
involves continuing to live with a suboptimal health state with a utility weight less than 1 
and the other involves a hypothetical cure which will either restore one to perfect health or 
kill one immediately. The SG utility weight is 1 minus the probability of death at which the 
respondent is indifferent. TTO asks people how many years of life they would be willing to 
give up at the end of their lifespan to be restored to full health now. VAS is simpler to use 
because it only asks people to fill out a rating scale and is readily self-completed but VAS is 
not a choice-based measure and hence cardinal VAS preferences may be misleading [18]. 
Also, VAS estimates have a wider dispersion, with lower values for most conditions than is 
true for SG or TTO [17].
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The SG yields weights that are generally higher than those that result from use of a TTO 
method [14,19]. This difference may reflect biases in how people respond to SG questions 
[20]. In addition, standard expected utility theory may not reflect how people value 
uncertain outcomes; rank-dependent expected utility theory and cumulative prospect theory 
allow for nonlinear weighting of probabilities and differential aversion for losses and gains. 
Evidence of risk perceptions calculated using a discrete choice experiment suggests that SG 
typically overstates utilities and that utility values are more consistent with a rank-dependent 
expected utility function [21]. Other researchers have also used different methods of 
pairwise comparisons based on discrete choice experiment to elicit preferences on health 
states [22,23].
More commonly, utility scores are assessed indirectly by asking people to fill out a 
questionnaire using a multi-attribute survey that describes health on multiple domains, each 
of which has multiple levels. The surveys are generic measures that can be used on their 
own to measure HRQL or in combination with preference-based valuation sets to generate 
health utilities. For the latter, numerical scores for each combination are assigned values that 
are derived from a population-based survey or exercise in which direct utility elicitation 
methods were used to assess trade offs among hypothetical health states. The combination of 
a descriptive questionnaire and the values assigned to each combination of score is known as 
a multi-attribute utility assessment instrument (MAUI). The choice of instrument in 
principle should depend on what aspects of health the potential researcher or policy body 
wishes to cover as well as the disease type and age group of patients being evaluated.
As seen in Table 2, six MAUIs are commonly used [24], of which three have been used in 
research with people with hemophilia. Two were developed as stand-alone MAUIs, the 
Euro-Qol EQ-5D and the Health Utilities Index (HUI), each of which has more than one 
version. The EQ-5D has five domains: mobility, self-care, usual activities, pain/discomfort 
and anxiety/depression with three levels for each (now known as the EQ-5D-3L to 
distinguish it from a new version with five levels, the EQ-5D-5L, whose valuations are still 
being developed) [25]. The HUI2 [26] was developed specifically for use with children and 
has six dimensions (plus a fertility dimension that is usually excluded); the HUI3 is targeted 
for adults and adolescents. The HUI3 split the HUI2 sensory dimension into separate 
hearing, speech and vision dimensions [27,28].
Each MAUI has values assigned to health states based on surveys of members of the public. 
The HUI uses SG valuations derived from a Canadian sample taken to be representative of 
the general community. The SG utilities for the HUIs were derived from VAS values using a 
power transformation based on a subset of respondents and health states for which both SG 
and VAS valuations were available [18]. The use of power transformation methods has been 
debated [29,30]. However, the HUI3 scoring function was validated in a study which 
compared predicted and directly measured SG scores for 73 health states [27].
The EQ-5D has multiple sets of valuations for various countries, in addition to a VAS-based 
measure (EQ-5D-VAS). The EQ-5D valuations employ the TTO method, with a 10-year 
time horizon typically employed. However, the choice of a time horizon for TTO preference 
elicitation is arbitrary, and TTO values have been shown to be sensitive to the length of the 
Grosse et al. Page 4













time horizon [31]. Valuations for the same EQ-5D health state using different national 
‘tariffs’ (valuations assigned to EQ-5D combinations, the product of which yield utility 
weights) can differ appreciably, which has implications for cost–effectiveness analyses [32]. 
For example, Noyes et al. found the ICER for a particular drug therapy to be US$42,899 
using the UK scoring function and US$108,498 using the US weights [33]. That may be a 
relatively extreme example, though.
Indirect preference-based measures of utility can be calculated using algorithms derived 
from non-preference-based HRQL instruments. To do so, a utility elicitation protocol is used 
with a representative sample of adults to derive valuation sets for the various health states 
represented by combinations of responses to the HRQL questions. For example, the Rand 
Short-Form HRQL instrument with either 36 (SF-36) or 12 (SF-12) questions produces 
separate component scores for physical (PCS) and mental (MCS) health. A group in Britain 
developed a preference-based MAUI with six domains, the SF-6D (Table 2) that through 
algorithms based on subsets of questions from the SF-36 or SF-12 instruments using values 
calculated through a SG exercise in a population sample can be used to calculate utility 
weights [34,35]. The US weights for the SF-6D have recently been developed using an 
innovative pairwise pivot method [23].
The different MAUIs can yield different estimates of utility weights for a given health state 
or disorder both as overall means and in terms of responsiveness to clinical differences. 
Although differences in values for health states between MAUIs often have relatively minor 
impacts on ICERs [29], examples of large discrepancies can be found. For example, a 
British study of hearing aid fitting in older adults reported that mean utilities calculated 
using the EQ-5D, SF-6D (both using UK weights) and the HUI3 were 0.80, 0.78 and 0.58, 
and the pre-post difference was 0.01, 0.01 and 0.06, respectively [36]. Unlike the EQ-5D or 
SF-6D, the HUI3 has a separate domain for hearing, which presumably accounts for the 
greater apparent sensitivity of that instrument to hearing loss. A Canadian study of adults 
with breast, colorectal or lung cancer reported that the difference in utility weights between 
advanced stage cancers and less advanced cancers was 0.01 using the EQ-5D and SF-6D and 
0.05–0.06 using HUI2 and HUI3, a fivefold difference in the apparent impact of advanced 
cancer using HUI2 and HUI3 versus EQ-5D or SF-6D [37]. Teckle et al. note that the 
EQ-5D and SF-6D have domains of role and social function that can reflect adaptation to 
physical limitations, whereas the HUI instruments have domains for impairments, but do not 
have domains that reflect adaptation (Table 1) [37].
In addition to differences in the types of domains included, the commonly used MAUIs 
differ in terms of ceiling and floor effects. The EQ-5D has ceiling effects, with many values 
of 1.0 and no values between 0.88 and 1.0, whereas the SF-6D has values that are more 
tightly compressed, with a floor at 0.30 [29,38]. The HUI3 has the greatest dispersion in 
scores and tends to yield a larger estimate of difference in scores associated with 
interventions. That is particularly true for vision and hearing, which are distinct domains in 
the HUI3 (Table 2), but are not included in the EQ-5D or SF-6D [16].
A number of head-to-head comparisons of the EQ-5D and SF-6D have been published [29]. 
At the individual level, the correlation of the two measures is moderate, typically with a 
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correlation coefficient of about 0.7. The EQ-5D generally does a better job of discriminating 
among severe health states and the SF-6D is better at discriminating among people with 
relatively mild health states (Table 2). The two instruments often yield non-comparable 
mean estimates [39,40]. Consequently, there may be value in collecting both SF-6D and 
EQ-5D scores and using both to estimate QALY gains for CUAs.
Most MAUIs, except for the HUI2, were developed for use with adults or adolescents, 
although the EQ-5D has been used by some researchers with pediatric samples, and a 
variant, the EQ-5D-Y, was designed to be applied to children or adolescents [40]. The HUI3 
can be taken directly by adolescents aged 13 years and above and can also be administered 
to parents of younger children [41]. The assessment of health utilities in children is a 
challenging field [32,42,43].
The choice of utility elicitation method to calculate utility scores may depend on the 
intended policy audience. Some organizations, notably NICE in the UK, use cost per QALY 
thresholds to make coverage decisions for prescription medications. NICE strongly 
recommends the use of the EQ-5D for valuing health outcomes in cost–effectiveness 
analyses for pharmaceuticals, whereas France appears to prefer direct utility elicitation 
methods and several European countries as well as Canada indicate method agnosticism. In 
some countries, this lack of preference may reflect lack of interest or support for QALY 
measures more generally [31,44]. The USA has no official guidance, but two influential 
panels of experts indicated a preference for use of MAUIs, although accepting direct 
methods such as SG and TTO [1,45].
Methods
One of the authors as a first step identified published studies that used empirical data to 
model the impact of prophylaxis on health utilities among adults with hemophilia. PubMed 
was initially searched in 2012 for articles referring to ‘cost–effectiveness’ ‘hemophilia’ and 
‘prophylaxis’; a total of five cost-utility studies were identified. The search was repeated in 
April 2013 and one additional CUA was identified [5] as well as a review [3]; a hand search 
of references confirmed the exhaustiveness of the list of CUAs. Two CUAs of treatment for 
hemophilia inhibitors in adolescents and adults were also identified through a search of the 
Tufts CEA Registry. In a second step, CUAs were reviewed to identify the sources of 
estimates of utility weights. In addition, searches were conducted in PubMed and Google 
Scholar (which allows full-text searches) for studies that elicited health utilities in 
hemophilia patients by using the names of specific utility elicitation methods in combination 
with ‘hemophilia’. Those searches were repeated in February 2014 and May 2014.
Several different study designs have been used to assess health utilities among individuals 
with hemophilia. One approach is to ask hypothetical questions about different hemophilia 
treatment states among people familiar with hemophilia, with direct utility elicitation 
methods. Three other study designs use indirect utility elicitation and cross-sectional data. 
The simplest of these approaches is a comparison of mean utility weights for individuals 
using prophylaxis with those receiving on-demand treatment, holding constant the severity 
of hemophilia. However, this approach will likely understate the actual impact of 
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prophylaxis if people with severe hemophilia who experience bleeding events less 
commonly are less likely to use prophylaxis on a regular basis. Another approach presumes 
that the effect of prophylaxis is to turn the patient with severe hemophilia into the equivalent 
of someone who has moderate hemophilia and takes the difference in mean utility weights 
for patients with severe and mild/moderate hemophilia, few or none of whom are on 
prophylaxis, as equivalent to the expected impact of prophylaxis among males with severe 
hemophilia. A third approach is to use retrospective data to assess the cumulative lifetime 
use of prophylaxis as the independent predictor of utility weights.
Results
Utility weights for adults with hemophilia
As seen in Table 3, 17 sets of published estimates of utility weights for adult and adolescent 
males with hemophilia were identified. Two studies used direct utility elicitation with SG 
[46,47]. Fifteen studies used indirect elicitation, 11 of which used the EQ-5D [9,48–57]. 
HUI measures were used in two studies [58,59], and the SF-6D was used in another two 
studies [60,61].
SG estimates
A SG exercise with seven hypothetical health scenarios was conducted in Canada with 30 
members of the public, 30 parents of children with hemophilia and 28 adults with 
hemophilia [46]. Adults with hemophilia were the least willing to accept a risk of death to 
avoid poorer health states, and members of the general public were most willing to accept a 
risk of death to achieve a hypothetical cure. Consequently, SG utility weights were higher 
for adults with hemophilia than in the general population and were also higher for parents of 
children with hemophilia. For each group, the least preferred scenario was on-demand 
therapy with frequent bleeding (≥3 bleeds in 3 months), with a median value of 0.825 in the 
general population and 0.895 among adult patients. The baseline scenario of on-demand 
therapy with less frequent bleeds (<3 in 3 months) had median SG weights of 0.905 and 
0.940, respectively, compared with 0.950 and 0.955, respectively for highdose prophylaxis 
in the absence of a port [46]. In addition, the disutility of having a target joint was modeled, 
with the results used in a CUA [8].
A second SG study was conducted in the USA with 64 adults with hemophilia and 64 
children, most of whom had parent proxy respondents (VAS scores were also assessed) [46]. 
The respondents chose among nine health states. The mean SG scores for mild hemophilia 
for the adult samples were 0.884; for moderate hemophilia, 0.868; for severe hemophilia on 
episodic treatment with no significant joint disease, 0.810 and for severe hemophilia on 
prophylaxis with no significant joint disease, 0.799. If one compares the mean scores for the 
two groups of hypothetical severe hemophilia patients without joint disease, episodic 
treatment versus prophylaxis was associated with a difference in health utility of +0.11 for 
the adult sample, indicating no reduction in utility with episodic treatment per se. Average 
utilities were lower for scenarios with severe joint disease, but no comparison was made for 
treatment types for those scenarios. In addition, presence of HIV or hepatitis C virus (HCV) 
infection and severe liver disease were each associated with major decrements in utility. 
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Having an inhibitor was associated with significantly lower scores, 0.745, equivalent to a 
decrement of roughly 0.06 relative to severe hemophilia without joint disease [47].
EQ-5D estimates
A cross-sectional UK sample of 249 adult males with hemophilia, none of whom received 
prophylaxis, were administered both the SF-36 and the EQ-5D; usable data were available 
for 166 subjects [43]. According to that study, 66 males with severe hemophilia had a 
median EQ-5D weight of 0.66, compared with a median weight of 0.85 for males with mild/
moderate hemophilia. Miners et al. stated that neither EQ-5D nor SF-36 scores were 
significantly related to HIV seropositivity, history of bleeding or history of orthopedic 
surgery among the 66 subjects with severe hemophilia, but no results were reported. The 
EQ-5D score was most strongly associated with the pain component of the SF-36, followed 
by social functioning, general health perception and energy/vitality [48].
A smaller study of 56 patients with hemophilia in Italy, who were not on prophylaxis and 
did not have inhibitors, collected both EQ-5D and SF-36 information [49]. There was a 
marked decrement in EQ-5D scores with age: 0.81 at 15–30 years, 0.70 at 31–45 years and 
0.49 at 45 years or over. HIV infection had a large, negative effect that was independent of 
age, a regression coefficient of –0.180 [49].
A similar study from Italy applied the EQ-5D and SF-36 to 52 males aged 15–64 years with 
inhibitors [50]. The mean EQ-5D utility score was 0.66 calculated using the UK weights and 
0.69 using weights from Catalonia. The authors noted that this was comparable to the UK 
patients with severe hemophilia without inhibitors [48], but did not compare with the 
findings from an Italian study [49].
A multinational trial of a bypassing agent prophylaxis for a mix of pediatric and adult 
patients with inhibitors enrolled 37 patients and collected information prior to, during and 
post-prophylaxis for 22 who received prophylaxis [51]. Health utilities were elicited using 
EQ-5D index (referred to in the publication as TTO) scores. Mean EQ-5D scores increased 
from 0.56 pre-prophylaxis to 0.69 post-prophylaxis; median scores were 0.62 and 0.79, 
respectively.
Another trial of prophylaxis with a different bypassing agent collected EQ-5D index scores 
from 25 patients with inhibitors who completed the 12-month trial, 10 on prophylaxis and 15 
on on-demand treatment [52]. Mean scores increased from 0.62 to 0.70 for the prophylaxis 
group and remained essentially unchanged for the on-demand group, decreasing slightly 
from 0.63 to 0.61. The difference for the prophylaxis group was considered clinically 
significant. Results on EQ-5D index scores from a previous 6-month trial of the same agent 
were less favorable [62].
Another inhibitor-specific longitudinal study enrolled 18 adult patients and 19 caregivers of 
pediatric patients with inhibitors to fill out the EQ-5D [53]. For 18 adult patients, mean 
EQ-5D index values were 0.54 on days with bleeds and 0.74 on days without bleeds, or 0.72 
on average. Mean scores were higher for patients on prophylaxis, not controlling for age, but 
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pediatric patients were both more likely to receive prophylaxis and to have higher EQ-5D 
scores.
A sample of Dutch males with hemophilia, median age 62, who had undergone major joint 
surgery an average of 12 years earlier, responded to the EQ-5D [54]. Their mean EQ-5D 
score was 0.73, which compared with a Dutch norm of 0.84 for males aged 50–59 years.
Noone et al. conducted a telephone survey with 58 respondents with hemophilia living in 
four European countries: France, Ireland, Sweden and the UK [55]. The average EQ-5D 
weight was highest in Sweden, where prophylaxis was universal, 0.93, compared with 0.73–
0.76 in the other three countries where on-demand treatment was the norm. In addition, they 
reported pooled data stratified by individual lifetime experience with prophylaxis: 0.88 for 
those on lifetime primary prophylaxis, 0.77 for those with over 50% prophylaxis, 0.79 for 
those with less than 50% prophylaxis and 0.72 for those who had never received 
prophylaxis. Mean scores were 0.88 for those on primary prophylaxis and 0.78 for those on 
secondary prophylaxis. No data were collected on comorbid conditions such as infection 
with HIV or hepatitis C [55].
Noone et al. conducted a similar survey with 124 respondents from Canada, France, Ireland, 
the Netherlands, Poland and the UK, of which responses were used for 116 subjects aged 
18–35 years with severe hemophilia [56]. The use of on-demand treatment was 79% in 
Poland, 62% in France, 20% in Ireland, 13% in Canada and 8% in both the UK and the 
Netherlands. The mean health utility values for these countries were 0.629, 0.687, 0.786, 
0.791, 0.768 and 0.915, respectively. Excluding 13 respondents with a history of an inhibitor 
who were analyzed separately, the remaining sample was split into four groups: always on-
demand (n = 26), <50% of their life on prophylaxis (n = 26), ≥50% of their life on 
prophylaxis (n = 35) and always on prophylaxis (n = 15). Mean EQ-5D scores were 0.619 
for on-demand, 0.755 for those with less than half their life on prophylaxis, 0.812 for those 
mostly on prophylaxis and 0.866 for those always on prophylaxis. Parallel curves were 
observed when the sample was stratified by age into two groups. The mean score for the 
inhibitor cohort was 0.798, which is similar to the average score of those who were mostly 
on prophylaxis [9].
A recent study from the Netherlands assessed EQ-5D scores in young adults (aged 20–33 
years in 2007) with severe (n = 60) or moderate (n = 34) hemophilia seen at a hemophilia 
clinic in Utrecht, as well as unaffected controls (n = 105) [57]. All 60 severe patients had 
been on lifelong prophylaxis throughout childhood, beginning at a median age of 4.8 years, 
although 15% discontinued prophylaxis as adults. The authors reported that mean EQ-5D 
scores for patients with severe and moderate hemophilia were 0.80 and 0.92, respectively, an 
absolute difference of 0.12 (not statistically significant). The mean score for unaffected 
controls was 0.87. The authors concluded that quality of life was ‘similar’ for people with 
different levels of severity of hemophilia and with the general Dutch population [9].
A subsequent publication reported findings from EQ-5D data collected from males with 
severe hemophilia and no inhibitor [57]. The data were collected during regular outpatient 
visits between 2006 and 2009 from 78 Dutch adult patients and 50 Swedish patients seen at 
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participating hemophilia clinics, including a Utrecht clinic that was included in an earlier 
study [9]. All subjects with one exception in each country had been on prophylaxis since 
early childhood, although only 78% of the Dutch and 96% of the Swedish patients had 
remained on routine prophylaxis for the past 5 years. The mean EQ-5D scores, calculated 
using Dutch tariffs (valuation sets), were 0.88 for the Dutch sample and 0.86 for the 
Swedish sample, not significantly different from each other and 0.05 points lower than 
equivalent scores from the general male population aged 20–29 years in each country [57].
Other indirect utility elicitation estimates
A German study published in 1996 used an early version of the HUI instrument developed 
by Torrance to assess health utilities for 50 patients with hemophilia, 39 on episodic 
treatment and 11 on prophylaxis [58]. There was essentially no difference in mean utility 
values for the two groups, 0.60 and 0.59, respectively.
The impact of HIV status on the overall gap in utility scores is demonstrated in a Canadian 
study that reported HUI2 and HUI3 scores for 101 males aged 13 years or above stratified 
by HIV seropositivity among those with severe hemophilia. The absolute gap in scores 
between those with severe and mild/moderate hemophilia was 0.12–0.14, not taking HIV 
status into account (Table 3). Among HIV seronegative individuals with hemophilia, utility 
weights were lower among those with severe hemophilia by just 0.05–0.06, or by less than 
half as much as the overall difference [59].
A cross-national study collected SF-36 survey data from over 500 males aged 14–83 years 
with severe hemophilia and without an inhibitor in four European countries and used the 
SF-6D algorithm to generate utility scores that were included in a CUA of prophylaxis [60]. 
The mean predicted SF-6D utility scores for HIV-seronegative patients aged 30 years or 
under were 0.77 for those on prophylaxis and 0.73 for those treated on-demand, a difference 
of 0.04 [60]. Among subjects over age 30, mean scores did not differ significantly by 
treatment type. The multivariate regression used to predict scores controlled for age, 
disability and number of bleeds [60].
A Belgian study administered the SF-36 to 71 adult males seen at one treatment center [61]. 
The mean SF-6D utility score was 0.66, differing by severity: 0.63 for 44 with severe 
hemophilia, 0.66 for 15 with moderate hemophilia and 0.74 for 12 with mild hemophilia. 
The authors reported that adults with severe hemophilia were much more likely to have HIV 
and HCV infections than those with moderate hemophilia. Another publication from the 
same group of investigators reported that the decrements from the Belgian SF-6D norm for 
adult males were 0.197, 0.151 and 0.054, respectively [63].
Other studies have collected SF-36 or SF-12 data on patients with hemophilia [54,64–71]; 
those data could be used to generate SF-6D utility scores.
Expert commentary
Different approaches have been taken in the literature to estimate the disutility of on-demand 
treatment in severe hemophilia relative to prophylaxis. One approach entails the subtraction 
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of average utility weights for individuals with severe hemophilia from those with mild or 
moderate hemophilia on the assumption that prophylaxis will make people with severe 
hemophilia comparable to those with mild hemophilia [48]. Miners et al. reported an 
absolute difference of 0.19 points, equal to a relative difference of 20% in utility, between 
those with severe and mild/moderate hemophilia [48]. Three CUAs that used those data 
calculated that prophylaxis has a roughly 20% impact on QALYs and concluded that 
prophylaxis was cost-effective by usual criteria [4,6,7]. Another CUA of treatment for 
patients with inhibitors used the same utility scores [72].
The approach taken by Miners et al. has two limitations. First, much of the overall 
difference in utilities is likely to have been the result of confounding of severe hemophilia 
with HIV seropositivity. Barr et al. reported that when comparisons were restricted to HIV-
seronegative individuals, the difference in utility scores for those with severe versus mild/
moderate hemophilia A was only half as large as the overall difference [59]. Other 
investigators also reported significantly lower health utilities among patients with 
hemophilia with HIV infection [47,49].
Second, a Dutch study recently questioned the notion that lifelong prophylaxis can turn 
severe patients with hemophilia into the equivalent of moderate patients, because significant 
clinical differences remain [9]. Specifically, the median Haemophilia Joint Health Score 
measuring loss of joint function was four-times higher in the severe hemophilia group, 8 
versus 2. In contrast, the authors stated that EQ-5D scores for 80 patients with severe 
hemophilia who had been on lifelong prophylaxis were ‘similar’ to 40 patients with 
moderate hemophilia, 25% of whom were on prophylaxis. By ‘similar’, the authors meant a 
statistically non-significant difference. In absolute terms, however, the mean EQ-5D score 
for patients with severe hemophilia was 0.80 and that for moderate patients with hemophilia 
was 0.92, a difference of 0.12. The latter difference exceeds estimates of the minimally 
important difference for EQ-5D scores of 0.03–0.07, which is used to assess clinical 
significance [73,74]. Indeed, the disutility of severe relative to moderate hemophilia in that 
study is close to differences observed in the pre-prophylaxis era [59].
The utility estimates in the two CUAs that estimated very high ICERs were also subject to 
limitations. First, Lippert et al. estimated the effect of prophylaxis through the comparison 
of mean health scores for people with hemophilia in a clinical sample pooled from four 
European countries who did or did not use prophylaxis [60]. The difference of 0.04 for 
males under age 30 is one-fifth as large as in the CUA as noted by Miners [3,6]. However, 
that approach ignores selection bias [5]. If individuals with few complications are less likely 
to initiate or persist with secondary prophylaxis, an inverse association of prophylaxis with 
health scores could result. Similar average utilities could mask a beneficial effect of 
prophylaxis on health offset by an adverse selection bias. Two studies reported that the 
comparison of adults on secondary prophylaxis versus on-demand treatment leads to 
virtually no difference in SF-12 scores [64,65]. Two other studies reported very small, 
statistically insignificant differences in mean SF-6D or HUI scores by prophylaxis versus 
on-demand therapy [58,60].
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Second, the CUA by Risebrough et al. [8] used the SG results from Naraine et al. [46] using 
preferences from a general population sample with a direct effect of prophylaxis on utility 
scores of 0.045 and an indirect effect of target joint bleeds on utility scores of –0.08 [8]. It 
should be noted that the direct effect of prophylaxis on utility would have been one-third as 
large, 0.015, if adult patient preferences had been used, a phenomenon that has been noted 
previously [14]. Furthermore, SG results may overstate utility scores and understate the 
disutility of worse states of health [14]. On the other hand, Risebrough et al. modeled the 
effect of prophylaxis on the risk of developing a target joint in addition to a direct effect on 
health utility [8]. It appears that the difference in the expected number of target joints 
through age 6 between on-demand and primary prophylaxis in that model was 0.775, which 
implies a total utility gain from primary prophylaxis relative to on-demand treatment of 
0.107 per patient-year.
A recent CUA by Farrugia et al. [5] used estimates from a cross-national study that 
compared EQ-5D utility scores among persons with severe hemophilia living in six 
countries with different patterns of prophylaxis use to model the cost-utility of prophylaxis 
in the USA and UK [56]. Specifically, it was assumed that the mean utility scores under 
prophylaxis and on-demand treatment for a 20-year-old male would be roughly 0.886 and 
0.632, respectively, a difference of 0.25 [4]. Noone et al. reported that the mean utility score 
for individuals who reported always having been on prophylaxis was 0.866 and that of 
people always on-demand was 0.619 [56]. The comparison by Noone et al. of utility scores 
for reported history of primary prophylaxis, secondary prophylaxis and on-demand 
treatment reflects an important advance over previous studies, which compared current use 
of prophylaxis with on-demand therapy. The effect of secondary prophylaxis among people 
with established joint disease is likely to be very small [5,59]. One US study reported that 
six adults who had always used prophylaxis had higher scores on SF-12 dimensions than 
those who either used secondary prophylaxis (n = 26) or no prophylaxis (n = 32); the 
difference in one dimension, physical functioning, was statistically significant [64].
However, the mean scores by treatment type (always on-demand vs always on prophylaxis) 
in the study by Noone et al. appear to largely reflect between-country differences in mean 
utility scores, ranging from 0.629 in Poland to 0.915 in the Netherlands [56]. Consequently, 
the putative effect of prophylaxis on utility scores in that study and in the CUA by Farrugia 
et al. is confounded by cross-national differences in patterns of care, prevalence of chronic 
viral infections and socioeconomic conditions. It is implausible that the difference in mean 
utility scores between persons with severe hemophilia in Poland and the Netherlands could 
be due almost solely to differences in use of prophylaxis. Noone et al. could have estimated 
the association of treatment type with utility values within countries using a fixed effects 
(dummy variable) model.
Also, Noone et al. did not elicit HIV status from survey respondents, which has been shown 
to be an important con-founder in previous studies. Farrugia et al. [5] argue that the mean 
age of the sample, 18–35 at the time of the survey [56], was lower than the time elapsed 
since HIV infections occurred through contaminated blood products. However, the older 
half of the sample could have been subject to bias from unmeasured confounding with HIV 
Grosse et al. Page 12













seropositivity. That issue could be resolved through an analysis restricted to the younger half 
of the sample.
The cross-national studies by Noone et al. were based on convenience samples of persons 
with hemophilia and hence by definition are of uncertain representativeness. For The 
Netherlands, the mean EQ-5D score for self-selected Dutch young adult patients with severe 
hemophilia of 0.915 [56] is higher than that reported in two published reports from the 
Netherlands with representative samples of the treated population at a single center, 0.80 [9] 
and 0.88 [57].
The mean difference in utility scores between the prophylaxis and on-demand treatment 
arms of the three CUAs that reported favorable ICERs ranged from 0.21 [4,6,7] to 0.25–0.27 
at ages 0–20 years in the USA and UK and 0.33 in Sweden [5]. In contrast, the two CUAs 
with unfavorable ICERs assumed much lower differences in scores, 0.04 in one [60] and 
approximately 0.11 in the other [6]. The latter estimate is similar to the mean difference 
between patients with mild/moderate and severe hemophilia of roughly 0.12 reported in 
three studies [9,59,61].
None of the CUAs explicitly modeled the difference in utility associated with prophylaxis 
versus on-demand treatment. Each of the four analyses that reported relatively low ICERs 
included a probabilistic sensitivity analysis, but they modeled each utility score 
independently. For example, the analysis of Farrugia et al. preserved a difference of 0.25 in 
utility scores using either the lower or upper bound estimates for both scores [5]. In addition, 
a one-way sensitivity analysis in the same study varied each utility score by just 0.05, that is, 
a range of difference in utility scores from 0.20 to 0.30.
The choice of MAUI can be influential in estimates of utility scores in hemophilia. In 
particular, SF-6D utility scores in hemophilia appear to be lower than EQ-5D scores, 
although no direct comparisons have been published to date. The mean SF-6D score for 
patients with severe hemophilia in four European countries (Germany, Sweden, the UK and 
The Netherlands) was reported to be 0.70 [60], and for a sample of adults in Belgium it was 
0.63 [61]. Mean EQ-5D scores for males with severe hemophilia in Sweden and the 
Netherlands appear to be about 0.86–0.88 [57]. Mean EQ-5D scores for males with severe 
hemophilia in the UK are about 0.75–0.78 [55,56]. Through the Universal Data Collection 
(UDC) system, the US hemophilia treatment centers collected patient-reported EQ-5D and 
SF-12 data from thousands of individuals with hemophilia and other bleeding disorders 
between 2005 and 2011; EQ-5D data were previously used to estimate disability-adjusted 
life-years [75]. A head-to-head comparison of EQ-5D and SF-6D scores for more than 1800 
males with severe hemophilia A using these data is currently in preparation.
Generic MAUIs do not necessarily fully capture the adverse health effects of severe 
hemophilia. A recent study by den Uijl et al. [9] found a statistically insignificant difference 
in mean utility scores between individuals with severe and mild/moderate hemophilia. In 
contrast, that study found significant differences using the Haemophilia Joint Health Score 
instrument, which appears to be a more sensitive outcome measure in hemophilia. In studies 
with relatively small numbers of subjects, which is typical of rare disorders such as 
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hemophilia, it is challenging to find statistically significant differences in utility scores even 
if the differences are of clinically significant magnitude as was the case in the Dutch study 
[9].
Non-preference-based HRQL measures have also been used in studies of the benefits of 
secondary prophylaxis. Buchbinder and Ragni [76] identified nine studies of adult patients 
with hemophilia that compared measures of HRQL by prophylaxis status, of which six were 
said to report better HRQL among adult patients treated with prophylaxis compared with on-
demand therapy. However, it is not clear how many differences were statistically significant 
or clinically meaningful. An observational retrospective study from Italy with data on 37 
individuals reported that all EQ-5D dimensions were higher with prophylaxis; some (pain, 
mobility, usual activities) were statistically significant at the 0.01 level [77]. Pollmann et al. 
reported findings from 152 German adult subjects enrolled in the PASS study, of whom 103 
completed the SF-36 questionnaire [78]. The authors reported no differences by treatment 
type (on-demand vs continuous prophylaxis) in the MCS of the SF-36 and slight, not 
statistically significant differences in the physical health component (PCS). In contrast, both 
the presence of a ‘target joint’, a joint where bleeds frequently occur, and HIV infection 
were associated with statistically significant and clinically meaningful declines in the PCS; 
hepatitis C infection was not associated. The association of PCS with target joints was 
particularly strong [78].
Although the focus of the hemophilia literature on HRQL has been on joint bleeds and 
arthropathy, an important influence on the SF-36 PCS measure among people with 
hemophilia is pain [69]. Pain is included as a single attribute or dimension in HUI2, HUI3 
and EQ-5D. Among patients with hemophilia, self-reports of pain are associated with 
decreased EQ-5D scores [49]. Similarly, pain is one of two HUI3 attributes (along with 
ambulation) that significantly predicts overall HUI3 scores among individuals with 
hemophilia [59]. More attention should be paid to the role of pain management and self-
management strategies in improving outcomes for people with hemophilia.
Finally, there is potential value in the development of condition-specific preference-based 
measures (CSPBMs) for hemophilia. Disease-specific HRQL instruments are typically 
reported to be more responsive or sensitive in detecting relatively small but statistically 
significant and clinically important differences in functioning [79]. For example, a cancer-
specific preference-based instrument was able to detect significant differences that could not 
be picked up using either the EQ-5D or SF-6D, although HUI2 and HUI3 were found to be 
comparably sensitive to the cancer-specific instrument [37]. A CSPBM for rheumatoid 
arthritis was found to be only slightly superior to generic measures (HUI2, HUI3, EQ-5D 
and SF-6D), all of which were able to significantly discriminate differences in disease 
severity [80]. Despite the lack of clear evidence of utility of CSPBMs over generic 
measures, development of new measures continues to occur, motivated in large part by 
concerns over the insensitivity of generic measures [81,82]. An alternative is to abandon 
CUA and QALYs in favor of other metrics [11].
CSPBMs can be estimated in two ways, through statistical mapping in datasets where 
patients fill out both disease-specific instruments and generic preference-based measures or 
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through direct valuation in which people undergo direct utility elicitation for health states 
included in disease-specific instruments [83]. Utility weights for disease-specific measures 
derived from direct valuation are more likely to yield useful results than through statistical 
mapping algorithms, in part because the mapping algorithm is limited to the information 
content of the generic instrument such as the EQ-5D to which it is mapped [83]. For 
example, a preference-based instrument for osteoarthritis based on direct valuation was 
found to yield significant differences in utility weights for patients who had experienced 
significant improvement or deterioration in clinical measures whereas the HUI3 measure 
was not responsive [84].
As seen in Table 4, researchers from Germany developed hemophilia-specific HRQL 
questionnaires for children and adolescents [85] (Haemo-QoL) and for adults (Haem-A-
QoL) [86]. Culturally adapted and linguistically validated translations were developed so 
that these instruments could be used internationally [86]. Another disease-specific 
instrument, the Haemo-QoL-A, has been shown to discriminate significantly between adults 
with hemophilia by severity and HIV status, and the physical functioning subscale to 
discriminate between patients receiving prophylactic or on-demand therapy [87]. CHO-
KLAT is a disease-specific instrument developed by Canadian researchers with a focus on 
children’s perspectives [88]. CHO-KLAT was found to be a reliable and valid measure of 
quality of life for boys with hemophilia [89]. In the future, validated utility weights could 
potentially be derived from disease-specific instruments by measuring the impact on specific 
functionalities affected by the disease.
Five-year view
Future studies of HRQL in hemophilia will focus on using patient registries for longitudinal 
assessments and on having a robust study design with statistical methods that control for 
confounding by comorbid conditions (e.g., HIV or HCV infection). In addition, it is 
important for researchers to model the effects of prophylaxis on various complications of 
hemophilia as well as the disutility associated with those complications. For example, one 
SG study suggested that prophylaxis has little direct benefit among patients who do not have 
joint disease, but joint disease itself has a large negative effect on utility [47]. Since primary 
prophylaxis is known to reduce the frequency of joint disease, the total effect of prophylaxis 
requires modeling the probabilities of progressing to joint disease for the two treatment 
groups [90].
Study designs will allow for an increased understanding of the impact of timing of the start 
of prophylaxis, schedule of prophylaxis, severity of the disease and type of treatment on 
HRQL. These developments could help researchers quantify the degree to which frequent, 
intravenous infusions given several times weekly during prophylaxis influence HRQL. 
Finally, this will help in facilitating an increased understanding of the role of pain 
management and self-management strategies in improving health outcomes for people with 
hemophilia.
It also is anticipated that disease-specific measures will be used more frequently for 
assessing HRQL in children and adults with hemophilia motivated by the relatively small 
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differences in utility scores found using generic measures such as the EQ-5D. This could 
result in increased interest in preference-based scoring algorithms that could be used with 
hemophilia-specific HRQL instruments. However, mapping algorithms based on regression 
analyses that can be used to impute EQ-5D utilities from non-preference-based HRQL 
measures may not necessarily be reliable at the individual level, as shown by Blome et al. in 
the case of psoriasis [91]. However, empirical evidence comparing CSPBMs and generic 
instruments is mixed [82]. If such hypothetical CSPBMs do show greater responsiveness, 
which is uncertain, their use could potentially make interventions appear cost-effective 
relative to other interventions valued using generic measures more than could be justified. In 
order to inform prioritization decisions, generic instruments such as the EQ-5D, HUI3 or 
SF-6D will continue to be used [92].
CUAs of hemophilia prophylaxis will increasingly follow cost–effectiveness analysis 
guidelines and include utility scores in sensitivity analyses. Because even probabilistic 
sensitivity analyses often do not adequately capture uncertainty [93], it is important for 
sensitivity or scenario analyses to reflect the full range of variation in the published 
literature of differences in utility scores [32]. In addition to hemophilia prophylaxis with 
regular clotting factor, CUAs will continue to be used to compare management options for 
individuals with inhibitors, including prophylaxis with bypassing agents [94–96].
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• The hemophilia cost–effectiveness literature has struggled to assess the value of 
continuous prophylaxis versus on-demand or episodic treatment.
• Accurate estimates of quality-adjusted life-years associated with different 
hemophilia management strategies, including different prophylaxis protocols, 
are needed to assess cost-utility.
• Although indirect generic preference-based instruments such as EQ-5D, SF-6D, 
Health Utilities Index-2 and Health Utilities Index-3 allow researchers to 
estimate utility weights, studies using different instruments often find 
substantially different estimates and it is not clear which ones are most useful.
• Studies have reported small cross-sectional differences in utility scores by 
hemophilia severity, particularly if one controls for confounding by HIV 
infection.
• Males in countries where primary prophylaxis has been long promoted have 
significantly better utility scores than males in countries with less use of 
prophylaxis.
• The timing of the start of prophylaxis, schedule of prophylaxis, severity of the 
disease, type of treatment and presence of complications such as joint disease or 
an inhibitor may play an important role in health-related quality of life.
• It could be helpful to estimate the association of treatment type with utility 
values using a fixed effects (dummy variable) model to control for country of 
residence because currently, there is no published evidence on difference in 
utility weights in severe hemophilia by timing or duration of use of prophylaxis 
within national populations.
• Future research should focus on longitudinal assessments using registry data and 
on including controls for confounding by co-morbid conditions (e.g., HIV or 
hepatitis C virus infection).
• Disease-specific health-related quality of life instruments may be more sensitive 
than generic instrument in detecting relatively small but clinically important 
differences in outcomes while measuring a narrow aspect of functioning related 
to a disease. The development of mapping algorithms to derive utility measures 
from condition-specific instruments require vetting to demonstrate reliability 
and value.
Grosse et al. Page 22

























Grosse et al. Page 23
Table 1
Common direct elicitation methods (SG vs TTO vs VAS).
Technique Type Description Strength Weakness
SG Choice based Respondents explicitly 
trade off between 
health states and risk of 
death or life
• Rooted in rigorous 
theoretical foundation 
of expected utility 
theory (dominant 
theory of decision 
making)
• Favored by many 
health economists
• Cognitively challenging
• Valuations can be seen as 
containing biases (source of 
bias: probability weighting 
and loss aversion)
• SG yields weights that are 
generally higher than those 
that result from use of a TTO 
method
TTO Choice based Respondents are asked 
the number of years of 
life they would be 
willing to give up at 
the end of lifespan to 
be restored to full 
health now
• Favored by many 
health economists and 
also recommended by 
NICE in its technology 
appraisals
• Cognitively challenging
• Valuations can be seen as 
containing biases (source of 
bias: utility curvature, scale 
compatibility and loss 
aversion)
VAS Non-choice based Respondents are asked 
to fill out a rating scale 
comparing health states 
to death or perfect 
health
• Most feasible 
valuation technique
• High response rate and 
high levels of 
completion
• Prone to context effects 
(average rating for items is 
influenced by the level of 
other items being valued)
• Estimates have wider 
dispersion, with lower values 
for most conditions than 
estimated by SG or TTO
SG: Standard gamble; TTO: Time trade off; VAS: Visual analogue scale.
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